Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome
- PMID: 32990479
- DOI: 10.1080/14737159.2020.1830760
Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome
Abstract
Introduction: Coronavirus disease (COVID-19) can trigger a cytokine response storm (CRS) that is associated with high mortality but for which the underlying pathophysiology and diagnostics are not yet well characterized. This review provides an overview of the underlying immune profile of COVID-19-related CRS as well as laboratory markers for acute diagnosis and chronic follow-up of patients with SARS-CoV-2 and CRS.
Areas covered: Innate and acquired immune profiles in COVID-19-CRS, RNA-detection methods for SARS-CoV-2 in the setting of CRS including factors that affect assay performance, serology for SARS-CoV-2 in the setting of CRS, and other biomarkers for COVID-19 will be discussed.
Expert opinion: Studies support the implication of CRS in the pathogenesis, clinical severity and outcome of COVID-19 through the production of multiple inflammatory cytokines and chemokines from activated innate and adaptive immune cells. Although these inflammatory molecules, including IL-6, IL-2 R, IL-10, IP-10 and MCP-1, often correlate with disease severity as possible biomarkers, the pathogenic contributions of individual molecules and the therapeutic benefits of targeting them are yet to be demonstrated. Detection of SARS-CoV-2 RNA is the gold standard method for diagnosis of COVID-19 in the context of CRS but assay performance varies and is susceptible to false-negative results even as patients clinically deteriorate due to decreased viral shedding in the setting of CRS. Biomarkers including CRP, ferritin, D-dimer and procalcitonin may provide early clues about progression to CRS and help identify thrombotic and infectious complications of COVID-19.
Keywords: COVID-19; RNA; SARS-CoV-2; cytokine-release syndrome; cytokines; diagnosis; sensitivity.
Similar articles
-
SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.Front Immunol. 2021 Mar 1;12:629193. doi: 10.3389/fimmu.2021.629193. eCollection 2021. Front Immunol. 2021. PMID: 33732251 Free PMC article.
-
Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19.J Infect Dis. 2021 Apr 23;223(8):1322-1333. doi: 10.1093/infdis/jiab065. J Infect Dis. 2021. PMID: 33524124 Free PMC article.
-
Multiplex array analysis of circulating cytokines and chemokines in COVID-19 patients during the first wave of the SARS-CoV-2 pandemic in Milan, Italy.BMC Immunol. 2024 Jul 26;25(1):49. doi: 10.1186/s12865-024-00641-z. BMC Immunol. 2024. PMID: 39061002 Free PMC article.
-
SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.IUBMB Life. 2020 Nov;72(11):2331-2354. doi: 10.1002/iub.2379. Epub 2020 Sep 16. IUBMB Life. 2020. PMID: 32936531 Review.
-
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.Clin Microbiol Rev. 2021 May 12;34(3):e00299-20. doi: 10.1128/CMR.00299-20. Print 2021 Jun 16. Clin Microbiol Rev. 2021. PMID: 33980688 Free PMC article. Review.
Cited by
-
Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.Antiviral Res. 2023 Jun;214:105605. doi: 10.1016/j.antiviral.2023.105605. Epub 2023 Apr 15. Antiviral Res. 2023. PMID: 37068595 Free PMC article.
-
Laboratory Diagnosis for SARS-CoV-2 Infection.Infect Dis Clin North Am. 2022 Jun;36(2):327-347. doi: 10.1016/j.idc.2022.02.002. Infect Dis Clin North Am. 2022. PMID: 35636903 Free PMC article. Review.
-
Sex-disaggregated data confirm serum ferritin as an independent predictor of disease severity both in male and female COVID-19 patients.J Infect. 2021 Mar;82(3):414-451. doi: 10.1016/j.jinf.2020.10.012. Epub 2020 Oct 22. J Infect. 2021. PMID: 33131700 Free PMC article. No abstract available.
-
Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions.MedComm (2020). 2022 Dec 8;3(4):e196. doi: 10.1002/mco2.196. eCollection 2022 Dec. MedComm (2020). 2022. PMID: 36514781 Free PMC article. Review.
-
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.Cardiol J. 2022;29(5):739-750. doi: 10.5603/CJ.a2022.0072. Epub 2022 Aug 1. Cardiol J. 2022. PMID: 35912711 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous